MINDFuL

Phase 2 trial of XPro for early and mild Alzheimer’s disease

The MINDFuL study investigates XPro^TM in patients with mild cognitive impairment or Alzheimer’s disease with brain inflammation.

The MINDFuL study will compare XProTM to placebo (an injection that looks like the investigational drug but does not contain active medicine) to find out whether XProTM affects memory, functioning, and behavior. The study will also evaluate whether XProTM is safe and tolerable.

This study runs for 6 months in which some participants receive the study drug and some receive the placebo. During this time, measurements will be made by brain imaging (MRI), by blood collection, and cognitive testing. After this, a 12-month open label extension is offered in which all participants receive the study drug.